

**Congress of the United States**  
Washington, DC 20510

July 31, 2024

The Honorable Cathy McMorris Rodgers  
Chair  
Energy and Commerce Committee  
U.S. House of Representatives  
2125 Rayburn HOB  
Washington, D.C. 20515

The Honorable Frank Pallone  
Ranking Member  
Energy and Commerce Committee  
U.S. House of Representatives  
2322A Rayburn HOB  
Washington, D.C. 20515

Dear colleagues:

We appreciate your bipartisan leadership of the House Energy & Commerce Committee on many critical health care issues this Congress. Together, we have tackled complex challenges, like pharmacy benefit manager reform and health care price transparency, with the shared goal of ensuring that patients and our communities have what they need to meet their health care demands. In that spirit, we write to urge you to also consider a bipartisan path forward on strengthening the 340B Drug Discount Program. Recent court decisions, like *Genesis Health Care, Inc. v. Becerra* and *Loper Bright Enterprises v. Raimondo*, further underscore the urgent need for congressional action.

In June, the Energy & Commerce Oversight Subcommittee held a hearing on the 340B program. During the hearing, Members voiced bipartisan agreement that Congress should ensure covered entities are using their savings from the 340B program appropriately, and that low-income patients are receiving the benefits of those savings.

Recent reporting reflects a growing possibility that we may soon see substantive efforts proposed to strengthen the 340B program. We are all committed to the long-term viability of the program, and we are encouraged that a bipartisan group of Senators have invested years seeking wide stakeholder input and developing a set of policy reforms aimed at achieving consensus. Appropriately, their work so far has recognized the need for Congress to step in and provide clarity while ensuring patient well-being remains at the center of the program. As Members of Congress interested in preserving the 340B program for vulnerable patients and their communities, we want to be prepared and make sure the House has considered the full range of issues that will be involved in such an undertaking.

As the conversations and court cases around the 340B program continue, we urge your leadership to ensure that the Committee continues to serve as a forum for bipartisan collaboration so that our Members, the Health Resources and Services Administration, patient groups, covered

entities, manufacturers, and other stakeholders have an opportunity to be part of this important policy discussion.

Sincerely,



Scott H. Peters  
Member of Congress



Mariannette Miller-Meeks, MD  
Member of Congress



Nanette Barragán  
Member of Congress



Earl L. "Buddy" Carter  
Member of Congress

  
M.C.

Yvette D. Clarke  
Member of Congress



Larry Bucshon, MD  
Member of Congress




Jasmine Crockett  
Member of Congress



Diana Harshbarger, Pharm.D.  
Member of Congress



Don Davis  
Member of Congress



Blake D. Moore  
Member of Congress



Sylvia R. Garcia  
Member of Congress



Dusty Johnson  
Member of Congress



Joe D. Morelle  
Member of Congress



Vicente Gonzalez  
Member of Congress



Wiley Nickel  
Member of Congress



Mike Levin  
Member of Congress